Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Resectable Non-Small Cell Lung Cancer”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Large-scale testing (Phase 3)UnknownNCT06485557
What this trial is testing

A Prospective Cohort Study of Neoadjuvant Chemotherapy Plus Sintillumab in the Treatment of Resectable NSCLC

Who this might be right for
Resectable Non-small Cell Lung Cancer
Tang-Du Hospital 90
Testing effectiveness (Phase 2)Ended earlyNCT00298298
What this trial is testing

DNP-Modified Autologous Tumor Cell Vaccine for Resectable Non-Small Cell Lung Cancer

Who this might be right for
Non-Small Cell Lung Cancer - Completely Resectable
AVAX Technologies 6
Testing effectiveness (Phase 2)Looking for participantsNCT06241807
What this trial is testing

Neoadjuvant Camrelizumab Combined With Chemotherapy for Resectable Stage IIIA-IIIB NSCLC

Who this might be right for
IMMUNOTHERAPYNeoadjuvant TherapyResectable Lung Non-Small Cell Carcinoma+1 more
Shandong Cancer Hospital and Institute 30
Large-scale testing (Phase 3)Looking for participantsNCT07195695
What this trial is testing

Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutations

Who this might be right for
Non-small Cell Lung Cancer
Boehringer Ingelheim 400
Testing effectiveness (Phase 2)Ended earlyNCT03871153
What this trial is testing

Chemoradiation Plus Durvalumab Followed by Surgery Followed by Adjuvant Durvalumab in Patients With Surgically Resectable Stage III (N2) Non-Small Cell Lung Cancer

Who this might be right for
Non Small Cell Lung CancerStage III Non-small-cell Lung Cancer
Greg Durm, MD 7
Not applicableWithdrawnNCT01398124
What this trial is testing

Cyclin B1 Peptide-Pulsed Autologous Dendritic Cell Vaccine for Resectable Non-Small Cell Lung Cancer

Who this might be right for
Non-small Cell Lung Cancer
Milton S. Hershey Medical Center
Not applicableLooking for participantsNCT06756217
What this trial is testing

68Ga-grazytracer PET/CT for Early Assessment of Response to Neoadjuvant Immunotherapy in Resectable NSCLC

Who this might be right for
Non-Small Cell Lung Cancer
Ruijin Hospital 40
Not applicableLooking for participantsNCT07169708
What this trial is testing

A Retrospective Observational Study of Nivolumab in Combination With Chemotherapy as Neoadjuvant Therapy for Resectable NSCLC Patients: Real-World Experience in Taiwan (NEOREAL)

Who this might be right for
Non Small Cell Lung Cancer NSCLC
Ono Pharmaceutical Co., Ltd. 100
Not applicableLooking for participantsNCT05167487
What this trial is testing

Pathological Response After Neoadjuvant Treatment on NSCLC

Who this might be right for
Stage IIIA Non-small Cell Lung Cancer
Fundación GECP 150
Early research (Phase 1)Study completedNCT03732664
What this trial is testing

ICIs Neoadjuvant Therapy in Resectable Non-Small-Cell Lung Cancer

Who this might be right for
High-Risk Resectable NSCLC
Second Affiliated Hospital, Zhejiang University, School of Medicine 27
Testing effectiveness (Phase 2)Looking for participantsNCT05742607
What this trial is testing

IPH5201 and Durvalumab in Patients With Resectable Non-Small Cell Lung Cancer (MATISSE)

Who this might be right for
Non Small Cell Lung Cancer
Innate Pharma 70
Not applicableUnknownNCT04816838
What this trial is testing

A Window of Opportunity Study for Investigating Drug Tolerant Persister (DTP) to Neoadjuvant Osimertinib in Resectable Non-small Cell Lung Cancer (NSCLC) Harbouring EGFR Mutations

Who this might be right for
Non Small Cell Lung Cancer
Yonsei University 25
Not applicableLooking for participantsNCT06276530
What this trial is testing

Impact of Surgical Approach on Adaptation of Posture-respiratory Coupling

Who this might be right for
Resectable Lung Non-Small Cell Carcinoma
Assistance Publique - Hôpitaux de Paris 50
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07229339
What this trial is testing

Zipalertinib With Carboplatin and Pemetrexed for the Treatment of Resectable, Stage II-IIIB, Non-Small Cell Lung Cancer

Who this might be right for
Lung Non-Squamous Non-Small Cell Carcinoma
Jonsson Comprehensive Cancer Center 16
Testing effectiveness (Phase 2)Looking for participantsNCT07492342
What this trial is testing

Fulzerasib Sequential Sintilimab Plus Platinum-Doublet Neoadjuvant Therapy for Resectable KRAS G12C-Mutant NSCLC

Who this might be right for
Resectable NSCLCKRAS G12C MutationStage IB-IIIA NSCLC+1 more
Jianxing He 30
Not applicableStudy completedNCT00125372
What this trial is testing

Study of Tarceva and Targretin in Stage I-II Lung Cancer

Who this might be right for
Carcinoma, Non-small-cell Lung
Dartmouth-Hitchcock Medical Center 12
Early research (Phase 1)Study completedNCT04809103
What this trial is testing

Intratumoral Cisplatin for Resectable NSCLC

Who this might be right for
Non-Small Cell Lung Cancer
University of Vermont 6
Testing effectiveness (Phase 2)Ended earlyNCT04638582
What this trial is testing

Pembrolizumab as Neoadjuvant Therapy for Resectable Stage IA3 to IIA Non-Small Cell Lung Cancer (NSCLC)

Who this might be right for
Lung Cancer, Nonsmall Cell
McGill University Health Centre/Research Institute of the McGill University Health Centre 6
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07358689
What this trial is testing

Toripalimab Combined With Platinum-based Chemotherapy With or Without H1 Receptor Antagonist in the Perioperative Treatment of Resectable Non-small Cell Lung Cancer

Who this might be right for
NSCLC
Tianjin Medical University Cancer Institute and Hospital 120
Testing effectiveness (Phase 2)Active Not RecruitingNCT06161441
What this trial is testing

A Trial to Learn if the Combination of Fianlimab, Cemiplimab, and Chemotherapy is Safe and Works Better Than the Combination of Cemiplimab and Chemotherapy in Adult Patients With Non-Small Cell Lung Cancer That Can be Treated With Surgery

Who this might be right for
Resectable Non-small Cell Lung Cancer
Regeneron Pharmaceuticals 195
Next Page